A robust stability indicating HPLC technique for evalution of Pibrentasvir and Glecaprevir in tablet dosage form

When liver cells gets infected and vandalized, the condition is termed as Hepatitis. HCV therapy is performed with mixture of drugs. For the combined evaluation of Pibrentasvir and Glecaprevir in tablets, a rapid, selective and robust HPLC technique stability indicating was developed herein this work. Analysis was executed by Cosmicsil, with dimensions 250 mm by 4.6 mm column and mobile phase possessing KH2PO4 with 0.1M, 65 ml and 35 ml of methanol and 230 nm of PDA analysis. Elution times were found out as were 1.663 min and 2.249 min, for Pibrentasvir and Glecaprevir respectively with linear ranges 20µg/ml, 60 µg/ml and 50 µg/ml, 150 µg/ml, respectively having detection limits as 0.190 µg/ml and 0.207  µg/ml and quantization limits as 0.634 µg/ml and 0.690 µg/ml. This method is explicit having RSD values as 0.097% Pibrentasir & 0.232% Glecaprevir showing an accuracy of between 98.82 and 100.07% for Pibrentasir 99.31, Glecaprevir 100.45% recovery values. During the investigation of degradation, peaks elution times of degradants greatly varied with the elution times of Glecaprevir and Pibrentasvir thus, proving method‘s power of stability indication and specificity. The validation and degradation stability studies were carried out according to ICH and ICH Q1B Guidelines

A Study of Challenges and Recommendations for Teaching: DevOps Education

DevOps has gained significant popularity in the software industry due to its ability to enhance collaboration, improve software delivery, and drive organizational agility. However, providing effective education and training in DevOps poses several Issue. This research paper presents an interview study conducted with a seasoned DevOps professional to explore the challenges faced in DevOps education and provide recommendations for addressing these challenges. The study highlights the evolving nature of the DevOps landscape, the interdisciplinary nature of DevOps, and the need for hands-on learning experiences. Additionally, the study emphasizes the importance of continuous curriculum updates, practical exercises, cross-functional collaboration, industry partnerships, and fostering a continuous learning mindset. The findings from this study contribute to the understanding of the unique challenges and recommendations for improving DevOps education

Effect of renal impairment on the pharmacokinetics of exenatide

What is already known about this subjec

CT-DNA-binding and biological activity of mononuclear copper(II) complexes with imidazo-phenanthroline ligands

37-44Four imidazo-phenanthroline (IP) based ligands and its corresponding copper polypyridyl complexes have been prepared [Cu(L1-L4)2]2+ and characterized by various physicochemical techniques. Herein we are reporting the CT-DNA (calf-thymus DNA) binding & anti-cancer affinity of ligands (L1-L4) as well as complexes (C1-C4). The DNA binding affinity of synthesized C1-C4 has been carried out by using spectroscopic techniques like UV/visible, emission, molecular modeling and viscosity techniques. The obtained results are clearly indicating that all C1-C4 complexes bind to DNA via intercalative mode and they possess a significant cytotoxic effect toward selected cancer cell lines (MDA-MB-231, B16-F10, DU-145 and CHO-K1)

CT-DNA-binding and biological activity of mononuclear copper(II) complexes with imidazo-phenanthroline ligands

Four imidazo-phenanthroline (IP) based ligands and its corresponding copper polypyridyl complexes have been prepared [Cu(L1-L4)2]2+ and characterized by various physicochemical techniques. Herein we are reporting the CT-DNA (calf-thymus DNA) binding & anti-cancer affinity of ligands (L1-L4) as well as complexes (C1-C4). The DNA binding affinity of synthesized C1-C4 has been carried out by using spectroscopic techniques like UV/visible, emission, molecular modeling and viscosity techniques. The obtained results are clearly indicating that all C1-C4 complexes bind to DNA via intercalative mode and they possess a significant cytotoxic effect toward selected cancer cell lines (MDA-MB-231, B16-F10, DU-145 and CHO-K1)

Neurodevelopmental disorders in children aged 2-9 years: Population-based burden estimates across five regions in India.

BACKGROUND: Neurodevelopmental disorders (NDDs) compromise the development and attainment of full social and economic potential at individual, family, community, and country levels. Paucity of data on NDDs slows down policy and programmatic action in most developing countries despite perceived high burden. METHODS AND FINDINGS: We assessed 3,964 children (with almost equal number of boys and girls distributed in 2-<6 and 6-9 year age categories) identified from five geographically diverse populations in India using cluster sampling technique (probability proportionate to population size). These were from the North-Central, i.e., Palwal (N = 998; all rural, 16.4% non-Hindu, 25.3% from scheduled caste/tribe [SC-ST] [these are considered underserved communities who are eligible for affirmative action]); North, i.e., Kangra (N = 997; 91.6% rural, 3.7% non-Hindu, 25.3% SC-ST); East, i.e., Dhenkanal (N = 981; 89.8% rural, 1.2% non-Hindu, 38.0% SC-ST); South, i.e., Hyderabad (N = 495; all urban, 25.7% non-Hindu, 27.3% SC-ST) and West, i.e., North Goa (N = 493; 68.0% rural, 11.4% non-Hindu, 18.5% SC-ST). All children were assessed for vision impairment (VI), epilepsy (Epi), neuromotor impairments including cerebral palsy (NMI-CP), hearing impairment (HI), speech and language disorders, autism spectrum disorders (ASDs), and intellectual disability (ID). Furthermore, 6-9-year-old children were also assessed for attention deficit hyperactivity disorder (ADHD) and learning disorders (LDs). We standardized sample characteristics as per Census of India 2011 to arrive at district level and all-sites-pooled estimates. Site-specific prevalence of any of seven NDDs in 2-<6 year olds ranged from 2.9% (95% CI 1.6-5.5) to 18.7% (95% CI 14.7-23.6), and for any of nine NDDs in the 6-9-year-old children, from 6.5% (95% CI 4.6-9.1) to 18.5% (95% CI 15.3-22.3). Two or more NDDs were present in 0.4% (95% CI 0.1-1.7) to 4.3% (95% CI 2.2-8.2) in the younger age category and 0.7% (95% CI 0.2-2.0) to 5.3% (95% CI 3.3-8.2) in the older age category. All-site-pooled estimates for NDDs were 9.2% (95% CI 7.5-11.2) and 13.6% (95% CI 11.3-16.2) in children of 2-<6 and 6-9 year age categories, respectively, without significant difference according to gender, rural/urban residence, or religion; almost one-fifth of these children had more than one NDD. The pooled estimates for prevalence increased by up to three percentage points when these were adjusted for national rates of stunting or low birth weight (LBW). HI, ID, speech and language disorders, Epi, and LDs were the common NDDs across sites. Upon risk modelling, noninstitutional delivery, history of perinatal asphyxia, neonatal illness, postnatal neurological/brain infections, stunting, LBW/prematurity, and older age category (6-9 year) were significantly associated with NDDs. The study sample was underrepresentative of stunting and LBW and had a 15.6% refusal. These factors could be contributing to underestimation of the true NDD burden in our population. CONCLUSIONS: The study identifies NDDs in children aged 2-9 years as a significant public health burden for India. HI was higher than and ASD prevalence comparable to the published global literature. Most risk factors of NDDs were modifiable and amenable to public health interventions

EFFICACY OF PERIOPATCHTM – INTRA-ORAL WOUND DRESSING AS ADJUNCT TO SRP IN TREATMENT OF PERIODONTITIS

The mechanical disruption and removal of the bacterial biofilm via scaling procedures remains the cornerstone of periodontal treatment. The PerioPatch (Izun Pharmaceuticals, http://izunpharma.com) is an approved medical device product that is broadly intended for the management of all types of oral wounds, injuries, and ulcerations of the gingival and oral mucosa. The device is a self-adhesive hydrogel wound dressing that provides an absorptive and flexible barrier over the affected, inflamed gingival or mucosal area. Aim of this case series to test the efficacy of periopatch developed by Izun Pharmaceuticals (New York City) as adjunct to SRP in treatment of periodontitis. Results showed a mean pocket depth reduction of 2.1 mm in SRP with periopatch sites and 1.4mm reduction in control sites and CAL showed a gain of 1.9 and 1.1mm in test and control sites respectively. And bleeding site percentage was reduced from 100% in both groups to 11% in test group and 33% in control group. Within the confines of this case series, the PerioPatch is a novel but simple device that may be combined with scaling and root planing for the management of chronic periodontiti